In this work, we leveraged the breadth and depth of the electronic health care databases of the US Department of Veterans Affairs and methodologic advances to evaluate the comparative effectiveness of SGLT2 inhibitors vs sulfonylureas associated with the risk of all-cause mortality among individuals using metformin for treatment of type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.